본문 바로가기 주메뉴 바로가기

News & Media

Press Releases


Onselex Welcomes Two Distinguished Medical Innovators to its Clinical Advisory Board 

관리자 2022-11-02 21:16:10 Views 1,142

Onselex Welcomes Two Distinguished Medical Innovators to its Clinical Advisory Board 


October 15, 2022 


PROMINENT EXPERTS WILL GUIDE ONX-1006 INTO HUMAN PANCREATIC CANCER CLINICAL TRIAL 

 

 

Seoul, S. Korea, October 6, 2022 / -- Onselex Inc., a biotechnology company pioneering development of a novel class of drugs based on Nanoparticle delivery to treat Cancer and Neurological Diseases, formed its Clinical Advisory Board (CAB) by welcoming of two prominent leaders in the fields of cancer therapeutics. Joining Onselex's Clinical advisory board are Dr. Si-Young Song, Professor of the Yonsei University and a recipient of Yonsei Medical Grand Award; and Dr. Ho-Soon Choi, Hanyang University Medical Vice-Chancellor and Chief at Hanyang University Medical Center. 


With combined over 80 years of experience in cancer treatments, Dr. Song and Dr. Choi will contribute significant clinical guidance as the company advances its preclinical and clinical phases of ONX-1006 for treating pancreatic cancer. 


Professor Si-Young Song, graduated from Yonsei Medical School in 1983, and has served as the head of the Yonsei Medical Center Industry-University Cooperation Foundation, Dean of Yonsei University College of Medicine, and Dean of the Graduate School of Medicine.  Dr. Song also serves as Chairman of the Korean Health and Medical Technology Policy Review Committee, Ministry of Health & Welfare.  Formerly Dr. Song was President of the Korean Pancreatobiliary Association and Chairman of the Korean Society of Gastrointestinal Cancer Research.  Professor Song is a recipient of Red Stripes, South Korea's Order of Service Merit, for his outstanding service and duty.  Dr. Song said, "Reviewing the Onselex data, I sincerely hope that Onselex will be able to make a groundbreaking turning point that surpasses current pancreatic therapy; I will do my best."    


Professor Ho-Soon Choi, currently serves as a Hanyang University Medical Vice-Chancellor and Chief at Hanyang University Medical Center, one of best University hospitals in South Korea.  Over the course of his career, he has served as the Director of the Korean Society of Gastrointestinal Endoscopy and Chairman of the Korean Pancreatobiliary Association.  Dr. Choi also served as President of the Korean Society of Internal Medicine and was formerly the Dean of Hanyang University College of Medicine.  Dr. Choi said, "I am delighted and happy to join as a member of Onselex's Clinical Advisory Board.  With greater responsibility, I hope to contribute to Onselex's future Clinical program." 


The cancer therapeutic community has for decades sought to cure pancreatic cancer with many robust therapeutic and universal capabilities but mostly failed to achieve successful treatment. However, Onselex's ONX-1006 impressive pre-clinical data suggest successful pancreatic treatment is within reach.

 

Mr. Ernie Shin, President and CEO, said, "We are honored to have Dr. Song and Dr. Choi, world-renowned doctors and global scientists, on Onselex's Clinical Advisory Board.  Dr. Song and Dr. Choi have made extraordinary clinical and medical contributions throughout their distinguished careers.  Our CAB's strategic clinical and research expertise will be invaluable as Onselex continues to define and develop ONX-1006 based on its nanomedicine technology.  With our CAB's commitment to guide Onselex's development of ONX-1006, we will be aggressively advancing our ONX-1006 pancreatic clinical program."  

 

About Onselex Inc. 

A pioneer biotechnology company developing a novel class of drugs based on Nanoparticle delivery to treat Cancer and Neurological Diseases. Onselex develops new drugs built upon advanced nanoparticle encapsulation technology to treat cancer and neurological diseases. Targeted administration of certain oncology medications based on nanoparticle technology will reduce adverse reactions arising from the toxicity of oncology medications by more than 95 percent—compared to typical standard chemotherapy treatments—thereby significantly reducing cancer patients' suffering and effectively increasing the likelihood of complete recovery. 

 

CONTACTS : 

Bong Soo Kim, Onselex +82-2-2158-8174 

info@onselex.com  

SOURCE Onselex Inc.  

 

Prev
No previous posts.
Next
No next article.